Oncotelic Therapeutics Inc. (OTCQB: OTLC) venture Sapu Nano has secured approval from Australia's Human Research Ethics Committee (HREC) to begin enrolling patients in clinical trials for Sapu003, an injectable form of Afinitor (everolimus) for breast cancer treatment. This approval marks a significant step forward in the development of a novel delivery system for a drug that has been limited by oral formulation challenges.
Sapu003 utilizes Sapu Nano's proprietary Deciparticle technology to deliver everolimus directly into the bloodstream via intravenous injection. Everolimus, an mTOR inhibitor, is currently approved in oral form for certain cancers, including advanced breast cancer, but its absorption can be inconsistent. The Deciparticle platform aims to overcome these limitations by enabling full drug absorption, potentially achieving meaningful tumor shrinkage where oral formulations have been less effective.
"The approval of Sapu003 to enter human trials is a landmark moment. By enabling full drug absorption through intravenous delivery, this program has the potential to achieve meaningful tumor shrinkage where oral formulations have been limited," said Dr. Sud Agarwal, CEO of Ingenu, a contract research organization in Australia. "We are proud to support Sapu Nano in advancing this therapy, potentially giving breast cancer patients better outcomes and improved quality of life."
The clinical trial will evaluate the safety, tolerability, and pharmacokinetics of Sapu003 in patients with breast cancer. The approval from HREC, a key regulatory body in Australia, allows Sapu Nano to proceed with patient enrollment. The trial represents a critical milestone in the development of a therapy that could address a significant unmet need in breast cancer treatment.
Oncotelic Therapeutics is a clinical-stage biopharmaceutical company focused on oncology and immunotherapy products, particularly for high-unmet-need cancers and rare pediatric indications. The company owns a pipeline of drug candidates and benefits from the extensive patent portfolio of its CEO, Dr. Vuong Trieu, who has filed over 150 patent applications and holds 39 issued U.S. patents. Through joint ventures like Sapu Nano, Oncotelic advances select drug candidates. The company also holds a 45% stake in GMP Bio, a joint venture developing complementary therapies.
The approval of Sapu003 for clinical trials underscores the potential of innovative drug delivery technologies to improve the efficacy and tolerability of existing cancer therapies. If successful, Sapu003 could offer an alternative to oral everolimus, potentially leading to better outcomes for breast cancer patients. For more information about Oncotelic, visit the company's newsroom at https://ibn.fm/OTLC.
This development is part of a broader trend in oncology toward optimizing drug delivery to maximize therapeutic benefit. The Deciparticle technology could have applications beyond everolimus, potentially enhancing other cancer drugs with poor oral bioavailability. The results of the upcoming trial will be closely watched by the medical community and investors alike.
